deepull

Executive Summary

deepull is a Barcelona-based diagnostics company developing a novel direct-from-blood multiplex PCR platform aimed at rapid sepsis diagnosis. Founded in 2019, the company's technology can deliver 50 reportable results—including pathogen identification and antibiotic resistance markers—in approximately one hour, directly from a blood sample. This addresses a critical unmet need in sepsis management, where every hour of delayed appropriate therapy increases mortality. By enabling near-real-time, comprehensive molecular profiling, deepull's platform has the potential to significantly improve clinical outcomes and reduce healthcare costs associated with sepsis. The company operates in the highly competitive rapid diagnostics space but differentiates itself through its broad multiplexing capability and speed.

Upcoming Catalysts (preview)

• Q4 2026Completion of Clinical Validation Study70% success
• Q1 2027CE Marking Submission60% success
• Q3 2026Strategic Partnership with Hospital Network50% success